Original research

What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients?

Alisina Shahi, MDa, *, Thomas L. Bradbury, MDb, George N. Guild III, MDb, Usama Hassan Saleh, MDc, Elie Ghanem, MDd, Ali Oliashirazi, MDe

a Rothman Institute, Thomas Jefferson University, Philadelphia, PA, USA
b Orthopaedic Department, Emory University School of Medicine, Atlanta, GA, USA
c Orthopaedic Department, Med Care Hospital, Dubai, UAE
d Orthopaedic Department, University of Alabama, Birmingham, AL, USA
e Oliashirazi Institute at Marshall Orthopaedics, Marshall University, Huntington, WV, USA

ARTICLE INFO

Article history:
Received 30 November 2017
Received in revised form
25 February 2018
Accepted 28 February 2018
Available online 26 May 2018

Keywords:
Venous thromboembolism
Mortality
Incidence
Risk factors
Total hip arthroplasty
Total knee arthroplasty

ABSTRACT

Background: Pulmonary embolism and deep vein thrombosis, together referred to as venous thromboembolism (VTE), are serious and potentially preventable complications after total hip arthroplasty and total knee arthroplasty. The aim of this study was to investigate the incidence of mortality after VTE events and assess the risk factors that are associated with it.

Methods: The Nationwide Inpatient Sample was used to estimate the total number of total hip arthroplasty, total knee arthroplasty, VTE events, and mortality using the International Classification of Diseases, Ninth Revision procedure codes from 2003 to 2012. Patients’ demographics, Elixhauser, and Charlson comorbidity indices were used to identify the risk factors associated with in-hospital VTEs and mortality.

Results: A total of 1,805,621 THAs and TKAs were included. The overall rate of VTE was 0.93%. The in-hospital mortality rate among patients with VTEs was 7.1% vs 0.30% in patients without VTEs (P-value < .0001). The risk factors for mortality after VTE events in descending order were as follows: hypercoagulable state (odds ratio [OR]: 5.3, 95% confidence interval [CI]: 3.6-5.8), metastatic cancer (OR: 5.2, 95% CI: 3.3-5.6), myocardial infarction (OR: 4.2, 95% CI: 2.3-4.7), peripheral vascular disease (OR: 3.6, 95% CI: 3.2-4.0), cardiac arrhythmias (OR: 3.2, 95% CI: 1.6-4.3), advanced age (OR: 3.1, 95% CI: 2.3-3.7), electrolyte disorders (OR: 3.1, 95% CI: 2.2-3.6), pulmonary circulation disorders (OR: 2.9, 95% CI: 2.6-3.3), depression (OR: 2.8, 95% CI: 1.6-3.4), complicated diabetes (OR: 2.7, 95% CI: 2.1-3.2), weight loss (OR: 2.6, 95% CI: 2.2-3.3), renal failure (OR: 2.6, 95% CI: 1.7-3.5), chronic pulmonary disease (OR: 2.5, 95% CI: 1.3-3.1), valvular disease (OR: 2.4, 95% CI: 1.8-2.7), liver disease (OR: 1.7, 95% CI: 1.2-1.9), and obesity (OR: 1.6, 95% CI: 1.5-1.9).

Conclusions: In-hospital VTE has a significant in-hospital mortality rate. Several of the identified risk factors in this study are modifiable preoperatively. We strongly urge the orthopaedic community to be cognizant of these risk factors and emphasize on optimizing patients’ comorbidities before an elective arthroplasty.

© 2018 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

In the coming decade, the number of total hip and knee arthroplasties is projected to increase significantly in the United States and worldwide. Kurtz et al. [1] predicted that by 2030, number of primary total hip arthroplasties (THAs) increase by 174% and primary total knee arthroplasties (TKAs) by 672%. As with all medical procedures, total joint arthroplasty is often accompanied
by complications. Pulmonary embolism (PE) and deep vein thrombosis (DVT), together referred to as venous thromboembolism (VTE), are of the most dreaded complications after total hip and knee arthroplasties [2–4]. It has been shown that the median incidence of only in-hospital VTE events during the initial hospitalization is 0.59% (0.55%-0.63%) for primary total hip arthroplasty (THA) and 1.01% (0.94%-1.08%) for primary TKAs in the United States. This rate is significantly higher in revision total joint arthroplasties (up to 2.5%) compared to primaries (1.6%, P-value < .0001) [5]. This not only has a huge economical burden on patients and the health-care system but also can increase the hospital stay and be associated with significant increase in the mortality rate in patients undergoing total hip and knee arthroplasties [4–6].

Mortality is one of the most worrisome concerns for both the patient and surgeon following any surgical procedure. Despite this concern, to our knowledge, the in-hospital mortality of patients who developed VTE after total knee arthroplasty (TKA) and THA has not been studied. Thus, the aim of this study was to utilize the National Inpatient Sample (NIS) database to (1) identify the risk factors of in-hospital VTEs after TKA and THA, (2) determine the rate of in-hospital mortality in patients who developed VTE, and (3) define the risk factors for mortality in these patients.

Material and methods

Study design

To conduct this study, the NIS data from the Agency for Healthcare Research and Quality were used to establish an 10-year retrospective cohort of patients who underwent primary and revision THA and TKA in the United States between 2003 and 2012 [7]. The NIS is the largest longitudinal, all-payer hospital database in the United States. This database consists of more than 1000 hospitals annually with 7-8 million medical records, which approximately represents 20% of all hospital discharges in the United States. The NIS database contains patients’ demographics along with their comorbidities, duration of hospital stay, diagnostic codes based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), patient disposition/discharge destination, and total amount of in-hospital charges. Because of the fact that the available information from the NIS database is deidentified, this study was exempted from institutional review board approval.

Patient selection

The database was queried with ICD-9-CM codes: 81.51 and 81.53, and 00.70-00.73 to identify patient who underwent THA, and 81.54-81.55 and 00.80-00.84 codes for patients who underwent TKA. A total of 1,805,621 THAs and TKAs were identified for analysis including 520,590 primary THAs, 88,162 revision THAs, 1,101,205 primary TKAs, and 95,664 revision TKAs (Table 1).

Outcome variables and statistical analysis

All THA and TKA patients who developed pulmonary embolism ([PE]: ICD-9 codes 415.11 or 415.19) or deep vein thrombosis ([DVT]: ICD-9 codes 455.1, 451.2, 451.8, 451.9, 453.2, 453.4, 453.8, or 453.9) during their admission were identified. Mortality was used as the primary outcome measure; patients who developed VTE and expired during their admission were identified. Patients’ demographics including, gender, age, body mass index, and comorbidities using Charlson and Elixhauser indices were taken into account as the predictors for VTE and mortality. A logistic regression model was created using all the predictors.

Standard statistics were used to present the descriptive data. Chi-squared tests were used to compare the incidences. An alpha level of 0.05 was used to determine statistical significance. All the analyses were performed using R 3.1 (R Foundation for Statistical Computing, Vienna, Austria). The “survey” package for R was used to derive estimates of means, medians, standard deviations, standard errors, rates, and confidence intervals (CIs).

Results

The overall rate of in-hospital VTE in the NIS database among the 1,805,621 patients undergoing THA and TKA was 0.93% (10,218 DVT, 6620 PE, and 1072 with both DVT and PE; 16,838 cases of VTE total) (Table 2). The risk factors for developing in-hospital VTEs in descending order were hypercoagulable state (odds ratio [OR]: 4.8, 95% CI: 3.9-5.8), metastatic cancer (OR: 4.2, 95% CI: 3.1-5.0), renal failure (OR: 3.5, 95% CI: 2.4-3.7), pulmonary circulation disorders (OR: 3.4, 95% CI: 2.9-4.1), cerebrovascular disease (OR: 3.3, 95% CI: 2.9-4.1), dementia (OR: 3.2, 95% CI: 2.7-3.6), chronic pulmonary disease (OR: 2.7, 95% CI: 2.1-3.2), cardiac arrhythmias (OR: 2.2, 95% CI: 2.0-2.7), valvular disease (OR: 2.2, 95% CI: 1.7-2.5), fluid and electrolyte disorders (OR: 2.1, 95% CI: 1.9-2.2), weight loss (OR: 2.0, 95% CI: 1.7-2.5), lymphoma (OR: 1.8, 95% CI: 1.1-2.4), myocardial infarction (OR: 18.9, 95% CI: 16-19), congestive heart failure (OR: 1.7, 95% CI: 1.1-19), revision THA (OR: 1.4, 95% CI: 1.1-1.7), peripheral vascular disorders (OR: 1.4, 95% CI: 1.1-1.6), solid tumor without metastasis (OR: 1.3, 95% CI: 1.1-1.6), deficiency anemia (OR: 1.3, 95% CI: 1.1-1.4), advanced age (greater than 70 years old) (OR: 1.3, 95% CI: 1.1-1.4), obesity (OR: 1.2, 95% CI: 1.1-1.5), and female gender (OR: 1.1, 95% CI: 1.0-1.3).

The overall in-hospital mortality rate for THA and TKA without VTEs was 0.30% (5441/1788783). The in-hospital mortality rate among patients with VTE was 7.1% (1203/16388), which was significantly higher than those without VTE (P-value < .0001). The relative risk for mortality in patients with VTE was 23.5% (95% CI: 22.1-24.9) compared to those without VTEs. In-hospital PEs contributed the majority of mortalities in patients with VTE: 13.4% (887/6620) in PEs vs 3.1% (316/10218) in patients with DVTs (P-value < .0001). Patients who developed in-hospital PEs had a 1.9 relative risk for mortality (95% CI: 1.7-2.0) compared to those who just had DVTs. When THAs and TKAs were complicated with in-hospital PEs, the relative risk for mortality was 44.0% (95% CI: 41.2-47.1) compared to ones with no VTE events (number need to harm: 7.6). Furthermore, when adjusted for potential confounders and stratified by age, patients who developed VTEs had an odds ratio of 23.8% (95% CI: 21.5-26.8) for in-hospital mortality compared to those without VTEs.

Table 1

| Procedure | Number of patients | Mean age (95% CI) | Female gender (95% CI) |
|-----------|--------------------|-------------------|-----------------------|
| Primary THA | 520,590            | 67 (65-67)        | 57 (56-57)            |
| Revision THA | 88,162            | 67 (67-68)        | 58 (57-58)            |
| Primary TKA | 1,101,205         | 66 (66-67)        | 64 (63-64)            |
| Revision TKA | 95,664            | 66 (66-67)        | 58 (58-69)            |

Table 2

| Procedure | Pulmonary embolism (95% CI) | Deep venous thrombosis (95% CI) | Venous thromboembolism (95% CI) |
|-----------|-----------------------------|---------------------------------|---------------------------------|
| Primary THA | 0.41 (0.38-0.44)            | 0.24 (0.21-0.26)                | 0.60 (0.55-0.63)                |
| Revision THA | 1.12 (0.86-1.22)           | 0.37 (0.34-0.42)                | 1.36 (1.24-1.46)                |
| Primary TKA | 0.71 (0.57-0.77)           | 0.45 (0.42-0.48)                | 1.03 (0.94-1.09)                |
| Revision TKA | 0.93 (0.85-1.12)           | 0.35 (0.31-0.39)                | 1.17 (1.06-1.30)                |
The risk factors for mortality after VTE events in descending order were as follows: hypercoagulable state (OR: 5.3, 95% CI: 3.6-5.8), metastatic cancer (OR: 5.2, 95% CI: 3.3-5.6), myocardial infarction (OR: 4.2, 95% CI: 2.3-4.7), peripheral vascular disease (OR: 3.6, 95% CI: 3.2-4.0), cardiac arrhythmias (OR: 3.2, 95% CI: 1.6-4.3), advanced age (greater than 70 years old) (OR: 3.1, 95% CI: 2.3-3.7), fluid and electrolyte disorders (OR: 3.1, 95% CI: 2.2-3.6), pulmonary circulation disorders (OR: 2.9, 95% CI: 2.6-3.3), depression (OR: 2.8, 95% CI: 1.6-3.4), complicated diabetes (OR: 2.7, 95% CI: 2.1-3.2), weight loss (OR: 2.6, 95% CI: 2.2-3.3), renal failure (OR: 2.6, 95% CI: 1.7-3.5), chronic pulmonary disease (OR: 2.5, 95% CI: 1.3-3.1), valvular disease (OR: 2.4, 95% CI: 1.8-2.7), liver disease (OR: 1.7, 95% CI: 1.2-1.9), and obesity (OR: 1.6, 95% CI: 1.5-1.9). Table 3 provides the risk factors for VTE events and mortality for a side-to-side comparison.

**Discussion**

Complications after major surgery, including VTE, have been a well-established concern for clinicians. [8]. VTE is one of the most serious and potentially preventable complications after THA and TKA. Studies have shown that the venographic rates (asymptomatic serious and potentially preventable complications after THA and well-established concern for clinicians.[8]). VTE is one of the most

| Table 3 | Risk factors for VTE and mortality after VTE in total knee and hip arthroplasty patients. |
|---------|---------------------------------------------------------------|
| Variables | VTE OR Lower 95% CI Upper 95% CI | Mortality OR Lower 95% CI Upper 95% CI |
| Advanced age | 1.3 1.1 1.4 | 3.1 2.3 3.7 |
| Cardiac arrhythmias | 2.2 2 2.7 | 3.2 1.6 4.3 |
| Cerebrovascular disease | 3.3 2.9 3.6 | NS |
| Chronic pulmonary disease | 2.7 2.1 3.2 | NS |
| Congestive heart failure | 1.7 1.1 1.9 | NS |
| Deficiency anemia | 1.3 1.1 1.4 | NS |
| Dementia | 3.2 2.7 4.1 | NS |
| Depression | NS | 2.8 1.6 3.4 |
| Diabetes, complicated | NS | 2.7 2.1 3.2 |
| Female gender | 1.1 1 1.3 | NS |
| Fluid and electrolyte disorders | 2.1 1.9 2.2 | 3.1 2.2 3.6 |
| Hypercoagulable state | 4.8 3.9 5.8 | 5.3 3.6 5.8 |
| Liver disease | NS | 1.7 1.2 1.9 |
| Lymphoma | 1.8 1.1 2.4 | NS |
| Metastatic cancer | 4.2 3.1 5 | 5.2 3.3 5.6 |
| Myocardial infarction | 1.8 1.6 1.9 | 4.2 2.3 4.7 |
| Obesity | 1.2 1.1 1.5 | 1.6 1.5 1.9 |
| Peripheral vascular disorder | 1.4 1.1 1.6 | 3.6 3.2 4.0 |
| Pulmonary circulation disorders | 3.4 2.9 3.7 | 2.9 2.6 3.3 |
| Renal failure | 3.5 2.4 4.1 | 2.6 1.7 3.5 |
| Revision THA | 1.4 1.1 1.7 | NS |
| Solid tumor without metastasis | 1.3 1.1 1.6 | NS |
| Valvular disease | 2.2 1.7 2.5 | 2.4 1.8 2.7 |
| Weight loss | 2 1.7 2.5 | 2.6 2.2 3.3 |

NS, not statistically significant.
received no treatment. The authors concluded that patients who were clinically unsuspected to have PEs may remain undiagnosed and received no treatment. The authors concluded that patients who develop VTEs. Perhaps one of the most interesting risk factor was depression. This could be due to the disease itself or antidepressant agents that are commonly used by these patients. Parklin et al. [29] reviewed more than a million women through the National Health Service Breast Screening Program in England and Scotland. They reported that the risk of VTE is not increased in women who were diagnosed with depression; however, the use of antidepressants significantly increased the rates of VTE. There are also case reports of massive PE with the use of olanzapine [30]. In another study by Browne et al. [31], the authors found that depression was associated with a greater risk of postoperative psychosis (OR = 1.74), anemia (OR = 1.14), infection (OR = 1.33), and PE (OR = 1.20) after total joint arthroplasty.

Our study had several shortcomings, and our findings should be interpreted in light of these limitations. First, the inherent limitations with the NIS database; this database only includes inpatient information and it considers each hospitalization as a separate record. Therefore, we could only investigate in-hospital mortalities and VTE events during initial hospitalization, which represents a proportion of the total VTEs and mortalities that may occur after THA and TKA over a longer postoperative period when patients are being discharged [32–34]. Second, the NIS data does not differentiate between clinically significant and insignificant VTEs; purgently asymptomatic events may not have been captured. Third, the NIS database uses claims-based coding, which may contain coding variability and inaccuracies [35]. Fourth, we were also unable to evaluate the type of prophylactic modalities and the anticoagulant protocols that were applied for the management of VTE events. Fifth, because of the nature of the NIS database, patients who developed VTEs after their discharge and mortalities after discharge could not be investigated. Finally, the NIS database does not contain information about the cause of mortality in deceased patients.

Conclusions

Notwithstanding all of these limitations, this study is the first of its kind, to our knowledge, that reflects population-based estimates of in-hospital mortality after VTE events in THA and TKA patients. Based on the findings of this study, VTEs are beyond doubt one of the major causes of mortality after THA and TKA. Furthermore, using a regressing modeling strategy, this study identified several risk factors that are associated with increased mortality in these patients. Owing to the fatal consequences of the in-hospital VTE events, we strongly urge the medical community to recognize these risk factors and optimize the modifiable coverabilities before an elective arthroplasty.

References

[1] Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780.
[2] Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons Guidelines. J Arthroplasty 2008;23:42.
[3] Blom A, Pattison G, Whitehouse S, Taylor A, Bannister G. Early death following primary total hip arthroplasty: 1,727 procedures with mechanical thrombo-prophylaxis. Acta Orthop 2006;77:347.
[4] Guijarro R, Montes J, San Román C, et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011;105:610.
[5] Shahi A, Chen AF, Tan TL, Maltenfort MG, Kucukdurmaz F, Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J Arthroplasty 2017;32:1063.
[6] Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 1997;79:896.
[7] HCUP-US NIS Overview. https://www.hcup-us.ahrq.gov/nisoverview.jsp. [Accessed 16 July 2017].
[8] Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003;289:1868.
[9] Green WH, Pinoe GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S.
[10] Zahir U, Sterling RS, Pelegrimi VD, Forte ML. Inpatient pulmonary embolism after elective primary total hip and knee arthroplasty in the United States. J Bone Joint Surg Am 2013;95:e175.
[11] Pedersen AB, Baron JA, Overgaard S, Johnsen SP. Short- and long-term mortality following primary total hip replacement for osteoarthritis: a Danish Nationwide Epidemiological Study. J Bone Joint Surg Br 2011;93:172. https://doi.org/10.1302/0301-620X.93B2.25629.
[12] Lie SA, Engesæter LB, Havelin LI, Furnes O, Voldset SE. Early postoperative mortality after 67,548 total hip replacements. Acta Orthop Scand 2002;73:392.
[13] Badarudeen S, Shu AC, Ong KL, Baykal D, Lau E, Malkani AL. Complications after revision total hip arthroplasty in the medicare population. J Arthroplasty 2013;28:1954.
[14] Duncan CM, Gillette BP, Jacob AK, Sierra RJ, Sanchez-Sotelo J, Smith HM. Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty 2015;30:272.
[15] Heitjan DF, Cheng VC, Gore MP. Pulmonary embolism rates following total hip arthroplasty with prophylactic anticoagulation: some pulmonary emboli cannot be avoided. J Arthroplasty 2017;32:980.
[16] Hou H, Yao Y, Zheng K, et al. Does intermittent pneumatic compression increase the risk of pulmonary embolism in deep venous thrombosis after joint surgery? Blood Coagul Fibrinolysis 2016;27:246.
[17] Long G, Suqin S, Li G, Weihong Y, Zhenhu W. Impact of atrial fibrillation on postoperative outcomes after total knee arthroplasty: A retrospective study. J Int Angiol 2016;21:652.
[18] Zhang H, Mao P, Wang C, et al. Incidence and risk factors of deep vein thrombosis (DVT) after total hip or knee arthroplasty: a retrospective study with routinely applied venography. Blood Coagul Fibrinolysis 2017;28:126.
[19] Parvizi J, Huang R, Rezapoor M, Bagheri B, Maltenfort MG. Individualized risk model for venous thromboembolism after total joint arthroplasty. J Arthroplasty 2016;31:180.
[20] Shahi A, Parvizi J. Prevention of perioperative joint infection: pre-, intra-, and postoperative strategies. Med Flum 2015;51:103.
[21] Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty 2014;29:188.
[22] Mesko NW, Bachmann KR, Kovacevic D, LoGrasso ME, O’Rourke C, Froimson MI. Thirty-day readmission following total hip and knee arthroplasty — a preliminary single institution predictive model. J Arthroplasty 2014;29:1332.
[23] Gonzalez-Della Valle A, Lee Y, Saboie E, et al. One-year all-cause mortality of patients diagnosed as having in-hospital pulmonary embolism after modern elective joint arthroplasty is low and unaffected by radiologic severity. J Arthroplasty 2016;31:978.
[24] Bell TH, Berta D, Ralley F, et al. Factors affecting perioperative blood loss and transfusion rates in primary total joint arthroplasty: a prospective analysis of 1642 patients. Can J Surg 2009;52:295.
[25] Nevisier AS, Chang C, Lyman S, Gonzales Della Valle A, Haas SR. High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop 2010;468:115.
[26] Eyre RA, Goodman LR, Washington L. Clinicians’ response to radiologists’ reports of isolated subsegmental pulmonary embolism or inconclusive interpretation of pulmonary embolism using MDCT. Am J Roentgenol 2005;184:623.
[27] Goodman LR. Small pulmonary emboli: what do we know? Radiology 2005;234:654.
[28] Engelke C, Rummeny EJ, Marten K. Pulmonary embolism at multi detector CT of chest: one-year survival of treated and untreated patients. Radiology 2006;239:563.
[29] Parkin L, Balkwill A, Sweetland S, et al. Antidepressants, depression, and venous thromboembolism risk: large prospective study of UK women. J Am Heart Assoc 2017;6.
[30] Froimson MI. Thirty-day readmission following total hip and knee arthroplasty. Clin Orthop 1996;(333):27.
[31] Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 1997;79:896.
[33] Pellegrini VD, Donaldson CT, Farber DC, Lehman EB, Evarts CM. The John Charnley Award: prevention of readmission for venous thromboembolic disease after total hip arthroplasty. Clin Orthop 2005;441:56.

[34] Januel J-M, Chen G, Ruffleux C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 2012;307:294.

[35] Ching AC. How do we interpret national inpatient sample data about complications? Commentary on an article by Amit Jain, MD, et al.: “rhBMP Use in Cervical Spine Surgery: Associated Factors and In-hospital Complications”. J Bone Joint Surg Am 2014;96:e67.